PCN89 A COST EFFECTIVENESS ANALYSIS DEMONSTRATES THE BENEFITS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC ...
Oct 1, 2009, 00:00
10.1016/S1098-3015(10)74340-0
https://www.valueinhealthjournal.com/article/S1098-3015(10)74340-0/fulltext
Title :
PCN89 A COST EFFECTIVENESS ANALYSIS DEMONSTRATES THE BENEFITS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)74340-0&doi=10.1016/S1098-3015(10)74340-0
First page :
Section Title :
Open access? :
No
Section Order :
262